Login
$VNRX
$0.19 -$0.01 (2.8%) After hours

$VNRX 8-K SEC Filings

Filed On Filing
12 Nov 2026 8-K: Results of Operations and Financial Condition

Conference call to discuss financial and operational results scheduled for

12 Nov 2026 8-K: Departure/Election of Directors or Officers; Compensation

On November 10, 2026, Singapore Volition Pte. Limited (“Singapore Volition”), a wholly-owned subsidiary of VolitionRx Limited (the “Company”), and Mr. Cameron Reynolds, Chief Executive Officer and President of the Company, entered into a...

27 Oct 2026 8-K: Entry into a Material Definitive Agreement; Other Events

This Waiver and Consent (this “Waiver”) is entered into effective as of October 23, 2026 (the “Waiver Date”), by and between Lind Global Asset Management XII LLC, a Delaware limited liability company (“Lender” or “Holder”), and VolitionR...

25 Sep 2026 8-K: Unregistered Sales of Equity Securities

As previously reported, pursuant to that certain securities purchase agreement dated May 15, 2025 (as amended and restated on January 7, 2026, the “SPA”), VolitionRx Limited (the “Company”) issued to Lind Global Asset Management XII LLC,...

15 Sep 2026 8-K: Unregistered Sales of Equity Securities

As previously reported, pursuant to that certain securities purchase agreement dated May 15, 2025 (as amended and restated on January 7, 2026, the “SPA”), VolitionRx Limited (the “Company”) issued to Lind Global Asset Management XII LLC,...

14 Sep 2026 8-K: Other Events

VolitionRx Limited Announces Pre-Payment in Full of $7.5 million Senior Secured Convertible Promissory Note Due May 20, 2027

02 Sep 2026 8-K: Entry into a Material Definitive Agreement

This WAIVER AND CONSENT (this “Waiver and Consent”) is dated as of September 2nd, 2026 (the “Effective Date”), by and between VolitionRx Limited, a Delaware corporation (the “Company” or “Maker”), and Lind Global Asset Management XII LLC...

02 Sep 2026 8-K: Unregistered Sales of Equity Securities

As previously reported, pursuant to that certain securities purchase agreement dated May 15, 2025 (as amended and restated on January 7, 2026, the “SPA”), VolitionRx Limited (the “Company”) issued to Lind Global Asset Management XII LLC,...

24 Aug 2026 8-K: Unregistered Sales of Equity Securities

As previously reported, pursuant to that certain securities purchase agreement dated May 15, 2025 (as amended and restated on January 7, 2026, the “SPA”), VolitionRx Limited (the “Company”) issued to Lind Global Asset Management XII LLC,...

13 Aug 2026 8-K: Results of Operations and Financial Condition

Conference call to discuss financial and operational results scheduled for

07 Aug 2026 8-K: Unregistered Sales of Equity Securities

As previously reported, pursuant to that certain securities purchase agreement dated May 15, 2025 (as amended and restated on January 7, 2026, the “SPA”), VolitionRx Limited (the “Company”) issued to Lind Global Asset Management XII LLC,...

21 Jul 2026 8-K: Amendments to Articles/Bylaws; Change in Fiscal Year; Submission of Matters to a Vote of Security Holders

On July 17, 2026, VolitionRx Limited (the “Company”) filed a Certificate of Fourth Amendment (the “Amendment”) of the Second Amended and Restated Certificate of Incorporation (as amended, the “Restated Certificate”) with the Secretary of...

18 Jun 2026 8-K: Unregistered Sales of Equity Securities

As previously reported, pursuant to that certain securities purchase agreement dated May 15, 2025 (as amended and restated on January 7, 2026, the “SPA”), VolitionRx Limited (the “Company”) issued to Lind Global Asset Management XII LLC,...

10 Jun 2026 8-K: Entry into a Material Definitive Agreement; Other Events

This Securities Purchase Agreement (this “Agreement”) is dated as of June 7, 2026, between VolitionRx Limited, a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its succe...

22 May 2026 8-K: Entry into a Material Definitive Agreement

As previously reported, VolitionRx Limited (the “Company”) issued to Lind Global Asset Management XII LLC (“Lind”) (i) that certain senior secured convertible promissory note in the original principal amount of $7,500,000 on May 15, 2025...

15 May 2026 8-K: Departure/Election of Directors or Officers; Compensation

On May 12, 2026, Mickie Henshall notified the Board of Directors (the “Board”) of VolitionRx Limited (the “Company”) of her decision not to stand for re-election to the Board at the Company’s 2026 Annual Meeting of Stockholders (the “202...

14 May 2026 8-K: Results of Operations and Financial Condition

Conference call to discuss financial and operational results scheduled for

28 Apr 2026 8-K: Material Modification to Rights of Security Holders; Amendments to Articles/Bylaws; Change in Fiscal Year

VolitionRx Limited, a Delaware corporation (the “Corporation”), organized and existing under and by virtue of the Delaware General Corporation Law (the “DGCL”), does hereby certify that:

23 Apr 2026 8-K: Notice of Delisting or Failure to Satisfy a Listing Rule; Other Events

HENDERSON, Nev., April 23, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) (“Volition” or the “Company”), a multi-national epigenetics company, announced today that on April 22, 2026, the NYSE American LLC (the “NYSE Americ...

17 Apr 2026 8-K: Other Events

As previously disclosed under Item 5.07 of the Current Report on Form 8-K filed with the Securities and Exchange Commission on April 1, 2026, at a special meeting held on March 31, 2026, the shareholders of VolitionRx Limited (the “Compa...

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support